Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 5/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330962 | 0.92 | L3MBTL1 (0.32) | L3MBTL1AIMP2MC4RMTNR1B | |
| SCHEMBL3354707 | 0.90 | ALDH1A1 (0.34) | ALDH1A1PROKR1FPR2HSD11B1AIMP2 | |
| SCHEMBL3355341 | 0.89 | ALDH1A1 (0.34) | ALDH1A1PROKR1FPR2HSD11B1MC4R | |
| SCHEMBL3359004 | 0.89 | POLB (0.38) | ALDH1A1PROKR1FPR2HSD11B1L3MBTL1 | |
| SCHEMBL3353011 | 0.88 | LMNA (0.34) | ALDH1A1PROKR1FPR2L3MBTL1AIMP2 | |
| SCHEMBL3359075 | 0.88 | ALDH1A1 (0.33) | ALDH1A1PROKR1FPR2 | |
| SCHEMBL3352265 | 0.88 | ALDH1A1 (0.33) | ALDH1A1PROKR1FPR2HSD11B1 | |
| SCHEMBL3358333 | 0.88 | ALDH1A1 (0.33) | ALDH1A1PROKR1FPR2MC4RMTNR1B | |
| SCHEMBL3355876 | 0.87 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3359501 | 0.86 | ALDH1A1 (0.38) | ALDH1A1PROKR1FPR2L3MBTL1AIMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | claimed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | claimed |
| US-8759818-B2 | Deuterated compounds for electronic applications | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | ALDH1A1 903/4885PROKR1 148/4885FPR2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.